PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know

Organized by the SNMMI Outreach Domain:
Satellite Symposium in conjunction with the American Urological Association Annual Meeting.

This virtual session will take place on the AUA Annual Meeting platform and is open and free to all AUA attendees. Please note that pre-registration is encouraged but not required.

Date: September 12, 2021
Time: 9:00 - 10:30 am PT


This is presented as a Satellite Symposium in conjunction with the American Urological Association Annual Meeting.

CE Credit is available for this webinar.

Registration for this event is now closed. A recording of the event will be available on the SNMMI website soon.

This session will prepare urologists for the introduction of PSMA-targeted PET imaging to their clinical practice.

Session Description:
In recent years, a number of small molecules targeting prostate-specific membrane antigen (PSMA) have been developed for imaging with positron emission tomography (PET). At least one agent has already been approved by the U.S. Food and Drug Administration for use in imaging men with high-risk or biochemically recurrent prostate cancer, and additional agents are bound for approval in the coming year.

In this session, co-led by a nuclear radiologist and a urologist, we will discuss the basic principles of PET imaging and review the results from key trials of PSMA-targeted PET imaging. Through the review of selected scans and their findings, we will describe important clinical scenarios in which PSMA-targeted PET imaging is indicated, with a focus on initial cancer staging, biochemical recurrence, management of oligometastatic disease, and selection of candidates for PSMA-targeted endoradiotherapy.

In addition, through the examination of these images, we’ll walk attendees through the findings, allowing them to return to their practices with additional clarity in report interpretation and the ability to more confidently discuss case management with their patients.

Finally, we will review how one can start a program in PSMA-targeted PET imaging and expound upon the importance of the relationship between imagers and urologists, with a focus on the standardized reporting of imaging results.

Learning Objectives:

  1. Understand the fundamentals of PET imaging agents and image acquisition, and how those factors play into the choice of radiotracer for imaging of prostate cancer.
  1. Provide an introduction and understanding of basic PSMA PET image interpretation.
  1. Recall the key findings regarding sensitivity and specificity of PSMA PET imaging in common clinical scenarios.
  1. Recognize the appropriate clinical indications for PSMA-targeted PET imaging based on the available medical evidence.
  1. Apply knowledge learned at this session to establish a program in PSMA-targeted PET imaging.


Speakers:

Steven Rowe, MD
Assistant Professor of Radiology and Urology
Johns Hopkins University School of Medicine

Michael Gorin, MD
Urologist
Urology Associates & UPMC Western Maryland

This Satellite Symposium has been developed by the SNMMI and is supported by an educational grant from Lantheus Medical Imaging.

Pre-registration is not required.

CE Accreditation

 CME Accreditation – AMA PRA Credits

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SNMMI designates this online program for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must complete the online assessment and evaluation available after the program.

 

  The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Universal Activity Number: 0210-0000-20-017-H04-P Topic designations: H04=General Pharmacy Topics. This activity has been designated as knowledge-based CPE for Pharmacists. Total available credit for pharmacists is 1.0 hours or 0.1 CEUs.

To receive CPE credit, pharmacists must complete the post-program assessment and evaluation. You will have 3 attempts to pass the assessment with a score of 80%. Credit details will be uploaded to the National Association of Boards of Pharmacy (NABP) via the CPE Monitor within 14 days of evaluation completion. Evaluation must be completed by February 29, 2020. Pharmacists must include their NABP eProfile ID, which can be obtained at www.MyCPEmonitor.net.